RaymondPPerezMD

Oncology • Fairway, KS

Professor, Internal Medicine, University Kansas School of Medicine

Join to view full profile

Dr. Perez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Perez's full profile

Already have an account?

Office
KU Clinical Research Center
4350 Shawnee Mission Parkway
Fairway, KS 66205
Phone+1 913-945-5059
Is this information wrong?

Education & Training

Temple University HospitalFellowship, Hematology and Medical Oncology, 1988 - 1991
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1985 - 1988
Northeast Ohio Medical UniversityClass of 1985

Certifications & Licensure

KS State Medical License 2011 - 2017
NH State Medical License 1998 - 2012

Clinical Trials

A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors Start of enrollment: 2010 Mar 01
Terminated
Phase 1
A Study in Advanced Solid Tumors Start of enrollment: 2010 Jun 01
Completed
Phase 2
Study in Advanced Solid Tumors Start of enrollment: 2010 Apr 01
Completed
Phase 2
A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer Start of enrollment: 2011 Feb 01
Completed
Phase 1
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors Start of enrollment: 2012 Jun 28
Completed
Phase 1
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
Completed
Phase 1
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) Start of enrollment: 2012 Feb 27
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

2 citations
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.
Darcy B. Pooler, Dylan B. Ness, John Sarantopoulos, Nicholas Squittieri, Shoba Ravichandran, Carolyn D. Britten, Ravi K. Amaravadi, Ulka N. Vaishampayan, Patricia LoRu...> ;British Journal of Clinical Pharmacology. 2021 Mar 1
2 citations
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Lori J. Goldstein, Raymond P. Perez, Denise A. Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Ro...> ;Breast Cancer Research. 2020 May 20
54 citations
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Irene M. Ghobrial, Chia Jen Liu, Robert A. Redd, Raymond P. Perez, Rachid Baz, Oksana Zavidij, Romanos Sklavenitis-Pistofidis, Paul G. Richardson, Kenneth C. Anderson,...> ;Clinical Cancer Research. 2020 Jan 15
52 citations
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Lori J. Goldstein, Raymond P. Perez, Denise A. Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Ro...> ;Breast Cancer Research. 2020 Jan 10
1 citations
Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies.
Raymond P. Perez, Eric Chen, J. Thaddeus Beck, Keisuke Shirai, David N. Hayes, Tong Shen, John R. Baldwin, Katherine B. Bryant, Shuang He, Steve Chin> ;Pharmacology Research & Perspectives. 2019 Nov 25
21 citations
Primary lung mucoepidermoid carcinoma: analysis of prognostic factors using surveillance, epidemiology and end results program
Takefumi Komiya, Raymond P. Perez, Satomi Yamamoto, Prakash Neupane> ;The Clinical Respiratory Journal. 2017 Nov 1
65 citations
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion s...
Lainie P. Martin, Jason A. Konner, Kathleen N. Moore, Shelly Seward, Ursula A. Matulonis, Raymond P. Perez, Ying Su, Anna Berkenblit, Rodrigo Ruiz-Soto, Michael J. Birrer> ;Gynecologic Oncology. 2017 Nov 1
5 citations
Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.
Takefumi Komiya, Satomi Yamamoto, Anuradha Roy, Peter R. McDonald, Raymond P. Perez> ;Translational Lung Cancer Research. 2017 Oct 1
142 citations
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer
Anne F. Schott, Lori J. Goldstein, Massimo Cristofanilli, Pier Adelchi Ruffini, Susan McCanna, James M. Reuben, Raymond P. Perez, Giraldo Kato, Max S. Wicha> ;Clinical Cancer Research. 2017 Sep 15
76 citations
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Kathleen N. Moore, Hossein Borghaei, David M. O'Malley, Woondong Jeong, Shelly Seward, Todd M. Bauer, Raymond P. Perez, Ursula A. Matulonis, Kelli L. Running, Xiaoyan ...> ;Cancer. 2017 Aug 15
131 citations
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, o...
Kathleen N. Moore, Lainie P. Martin, David M. O'Malley, Ursula A. Matulonis, Jason A. Konner, Raymond P. Perez, Todd M. Bauer, Rodrigo Ruiz-Soto, Michael J. Birrer> ;Journal of Clinical Oncology. 2017 Apr 1
9 citations
Sponsors’ and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials:
Raymond P. Perez, Patrick Archdeacon, Nancy Roach, Robert Goodwin, Jonathan P. Jarow, Nina Stuccio, Annemarie Forrest> ;Clinical Trials. 2017 Mar 26
6 citations
Clinical Trial Electronic Portals for Expedited Safety Reporting: Recommendations from the Clinical Trials Transformation Initiative Investigational New Drug Safety Ad...
Raymond P. Perez, Shanda Finnigan, Krupa Patel, Shanell Whitney, Annemarie Forrest> ;JMIR Cancer. 2016 Dec 15
35 citations
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
Neeraj Gupta, Michael J. Hanley, Karthik Venkatakrishnan, Raymond P. Perez, Robin E. Norris, John Nemunaitis, Huyuan Yang, Mark G. Qian, Gerald Steven Falchook, Richar...> ;British Journal of Clinical Pharmacology. 2016 Sep 1
3 citations
TP53 Gene and Cancer Resistance in Elephants
Raymond P. Perez, Takefumi Komiya> ;JAMA. 2016 Apr 26
2 citations
Systematic analysis of design and stratification for phase III trials in first‐line advanced non‐small cell lung cancer
Takefumi Komiya, Raymond P. Perez, Kirsten D. Erickson, Chao H. Huang> ;Thoracic Cancer. 2016 Jan 1
1 citations
Infrequent chemoradiation-induced acute esophagitis in the Asian population: A meta-analysis of published clinical trials for unresectable stage III non-small cell lun...
Takefumi Komiya, Shana L. Palla, Feng Wang, Raymond P. Perez, Chao H. Huang> ;Thoracic Cancer. 2014 Nov 1
41 citations
Extracellular Membrane Vesicles Derived from 143B Osteosarcoma Cells Contain Pro-Osteoclastogenic Cargo: A Novel Communication Mechanism in Osteosarcoma Bone Microenvi...
Rama Garimella, Laurie Washington, Janalee Isaacson, Julian Vallejo, Madoka Spence, Ossama Tawfik, Peter S. N. Rowe, Marco Brotto, Raymond P. Perez> ;Translational Oncology. 2014 Jun 1
5 citations
Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxP...
TK Yeo, J Kintner, R. Armand, Raymond P. Perez, Lionel D. Lewis> ;Human & Experimental Toxicology. 2007 Dec 1
10 citations
Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
Alain C. Mita, Anthony J. Olszanski, Richard C. Walovitch, Raymond P. Perez, Kathleen Mackay, David Tuck, Cecilia Simmons, Susan Hammond, Monica M. Mita, Muralidhar Be...> ;Clinical Cancer Research. 2007 Jun 1
56 citations
Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850)
Raymond P. Perez, Lionel D. Lewis, Andrew P. Beelen, Anthony J. Olszanski, Nicholas Johnston, C. Harker Rhodes, Bernard B. Beaulieu, Marc S. Ernstoff, Alan Eastman> ;Clinical Cancer Research. 2006 Dec 1
22 citations
New targets and challenges in the molecular therapeutics of cancer.
Alan Eastman, Raymond P. Perez> ;British Journal of Clinical Pharmacology. 2006 Jul 1
10 citations
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic...
Ramesh K. Ramanathan, Sridhar Mani, Melvin Deutsch, Raymond P. Perez, Mark A. Ritter, Julie L. Eiseman, S. Percy Ivy, Donald L. Trump, Chandra P. Belani, Robert A. Par...> ;Cancer Chemotherapy and Pharmacology. 2006 Apr 1
57 citations
Docetaxel/Gemcitabine Followed by Gemcitabine and External Beam Radiotherapy in Patients With Pancreatic Adenocarcinoma
J. Marc Pipas, Richard J. Barth, Bassem I. Zaki, Michael J. Tsapakos, Arief A. Suriawinata, Michael A. Bettmann, Justin M M Cates, Gregory H. Ripple, John E. Sutton, S...> ;Annals of Surgical Oncology. 2005 Nov 1
Docetaxel/gemcitabine followed by gemcitabine and radiotherapy in patients with pancreatic adenocarcinoma.
Pipas JM, Barth RJ, Zaki B, Colacchio TA, Gordon SR, Sutton JE, Ripple GH, Tsapakos MJ, Cates JM, Perez RP> ;J. Clin. Oncol.. 2004-07-15
Join now to see all

Press Mentions

KU Cancer Center Makes Bid to Join Elite ClubSeptember 26th, 2016

Grant Support

Protocol-Specific Research SupportNational Cancer Institute2009–2012
Data And Safety MonitoringNational Cancer Institute2009–2012
SPRY2 Predicts Survival Post-Chemotherapy In Advanced Ovarian Cancer.National Cancer Institute2010
SPRY2 Predicts Survival Post-Chemotherapy In Advanced Ovarian Cancer.National Cancer Institute2009–2010
Inhibition Of S14 By Conjugated Linoleic Acid In Advanced Solid Tumor PatientsNational Cancer Institute2009–2010
Clinical ResearchNational Cancer Institute2004–2008
Modulation Of Clinical Sensitivity To ChemotherapyNational Cancer Institute2000–2004
Atorvastatin, A Prenylation Inhibitor In Acute Leukemia.National Cancer Institute2002–2003